These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 16155790)

  • 1. Breast cancer treatment and cognitive functioning: current status and future challenges in assessment.
    Castellon SA; Silverman DH; Ganz PA
    Breast Cancer Res Treat; 2005 Aug; 92(3):199-206. PubMed ID: 16155790
    [No Abstract]   [Full Text] [Related]  

  • 2. Is basic research providing answers if adjuvant anti-estrogen treatment of breast cancer can induce cognitive impairment?
    Buwalda B; Schagen SB
    Life Sci; 2013 Oct; 93(17):581-8. PubMed ID: 23353876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen.
    Castellon SA; Ganz PA; Bower JE; Petersen L; Abraham L; Greendale GA
    J Clin Exp Neuropsychol; 2004 Oct; 26(7):955-69. PubMed ID: 15742545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive impairment associated with adjuvant therapy in breast cancer.
    Bender CM; Sereika SM; Berga SL; Vogel VG; Brufsky AM; Paraska KK; Ryan CM
    Psychooncology; 2006 May; 15(5):422-30. PubMed ID: 16097037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive Deficits in Breast Cancer Survivors After Chemotherapy and Hormonal Therapy.
    Frank JS; Vance DE; Triebel KL; Meneses KM
    J Neurosci Nurs; 2015 Dec; 47(6):302-12. PubMed ID: 26447567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Follow-up of patients with early breast cancer.
    Sakemi H
    N Engl J Med; 2007 Sep; 357(10):1052-3; author reply 1053. PubMed ID: 17804856
    [No Abstract]   [Full Text] [Related]  

  • 7. Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study.
    Debess J; Riis JØ; Engebjerg MC; Ewertz M
    Breast Cancer Res Treat; 2010 May; 121(1):91-100. PubMed ID: 20306129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamoxifen and growth of an extrauterine leiomyoma.
    Bayya J; Minkoff H; Khulpateea N
    Eur J Obstet Gynecol Reprod Biol; 2008 Nov; 141(1):90-1. PubMed ID: 18848745
    [No Abstract]   [Full Text] [Related]  

  • 9. Cognitive limitations associated with tamoxifen and aromatase inhibitors in employed breast cancer survivors.
    Breckenridge LM; Bruns GL; Todd BL; Feuerstein M
    Psychooncology; 2012 Jan; 21(1):43-53. PubMed ID: 20967847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in adjuvant hormonal therapy for postmenopausal women.
    Strasser-Weippl K; Goss PE
    J Clin Oncol; 2005 Mar; 23(8):1751-9. PubMed ID: 15755983
    [No Abstract]   [Full Text] [Related]  

  • 11. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
    Tuxen MK; Nielsen DL; Lindberg H; Kamby C
    Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant chemotherapy and cognitive dysfunction in breast cancer patients.
    J Support Oncol; 2006 Feb; 4(2):66-7. PubMed ID: 16499119
    [No Abstract]   [Full Text] [Related]  

  • 13. Cognitive side-effects of adjuvant treatments.
    Burstein HJ
    Breast; 2007 Dec; 16 Suppl 2():S166-8. PubMed ID: 17719225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer treatment and cognitive function: the current state of evidence, underlying mechanisms and potential treatments.
    Vodermaier A
    Womens Health (Lond); 2009 Sep; 5(5):503-16. PubMed ID: 19702450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
    Baumann CK; Castiglione-Gertsch M
    Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microwave endometrial ablation for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Zhu Y; Yang J
    J Obstet Gynaecol Res; 2013 Sep; 39(9):1411-4. PubMed ID: 23815697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
    Wardley AM
    Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors.
    Schilder CM; Seynaeve C; Linn SC; Boogerd W; Beex LV; Gundy CM; Nortier JW; van de Velde CJ; van Dam FS; Schagen SB
    Crit Rev Oncol Hematol; 2010 Nov; 76(2):133-41. PubMed ID: 20036141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence to long-term adjuvant hormonal therapy for breast cancer.
    Gotay C; Dunn J
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):709-15. PubMed ID: 22098287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer.
    Lewis JD; Chagpar AB; Shaughnessy EA; Nurko J; McMasters K; Edwards MJ
    Cancer; 2010 May; 116(10):2307-15. PubMed ID: 20209619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.